Stage IIIB Cutaneous Melanoma AJCC v7 Recruiting Phase 3 Trials for Dabrafenib (DB08912)

IndicationStatusPhase
DBCOND0091048 (Stage IIIB Cutaneous Melanoma AJCC v7)Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02224781Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 MelanomaTreatment